Randomization
renal impairment, noncirrhotic NASH, well-compensated NASH cirrhosis, NASH, NASH cirrhosis
RENAL IMPAIRMENT
As specified in the protocol, the first 30 patients were enrolled in the OL 100 mg resmetirom arm (including any patients taking thyroxine >75 μg dPatients completing MAESTRO-NAFLD-1 were eligible to enroll in a 52-week OL extension (MAESTRO-NAFLD-OLE), which will provide additional data to characterize the safety and efficacy of resmetirom in adults with NAFLD/presumed NASH. In addition to the four arms described above, the MAESTRO-NAFLD-1 trial included three additional OL active treatment arms in patients with (1) noncirrhotic NASH, enrolled after the randomization period; (2) well-compensated (Child–Pugh A) NASH cirrhosis; and (3) moderate renal impairment. The OL arms in patients with at-risk NASH (enrolled after randomization period), well-compensated NASH cirrhosis and moderate renal impairment were completed after the main study and will be reported separately.